Jump to content
Powered by
  • BIOPRO BW
  • Healthcare industry
  • Bioeconomy

Healthcare industry

Main navigation

  • Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close
  • Databases

    Databases

    Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Article - 27/11/2017 Petri dish with nine square dark blue platelets under blue light.

    Antimicrobial layer expected to fight hospital acquired infections

    Infections caused by bacteria that contaminate the surface of medical devices such as catheters and wound dressings are not that rare and can even be life-threatening. However, at present there is no really effective way to keep these products germ-free until they are used. Scientists at the University of Freiburg have now developed a surface coating that reliably kills bacteria, but is harmless to human cells.

    https://www.gesundheitsindustrie-bw.de/en/article/news/antimicrobial-layer-expected-to-fight-hospital-acquired-infections
  • Article - 28/08/2017 Schematic showing the device and the test carrier.

    SpinDiag GmbH – rapid test makes it difficult for pathogens

    Antibiotic-resistant pathogens are becoming an increasing problem, especially in hospitals. Infected patients must be isolated as soon as possible. However, appropriate methods for testing patients upon admission to hospital and isolating them if necessary are still lacking. A young biotechnology company from Baden-Württemberg called SpinDiag GmbH has developed a cost-effective method for the rapid testing of microbial resistance in normal…

    https://www.gesundheitsindustrie-bw.de/en/article/news/spindiag-gmbh-rapid-test-makes-it-difficult-for-pathogens
  • Press release - 20/07/2017

    SpinDiag Raises 1.6 Mio. EUR Seed-Capital

    The Freiburg-based startup SpinDiag GmbH recently closed a 1.6 Mio. EUR seed-round with three private investors. The team developed a revolutionary point-of-care screening system for testing patients for antibiotic-resistant bacteria at their admission to hospitals and almost instantly so. The seed-capital will make it feasible to bring SpinDiag’s system from its current laboratory environment to first tests in hospitals.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/spindiag-raises-16-mio-eur-seed-capital
  • Article - 26/04/2017 Schematic representation of a mechanism leading to the fragmentation of amyloid fibrils.

    Chaperones disassemble Parkinson’s disease-specific amyloid fibrils

    Amyloid fibrils consisting of clumped α-synuclein protein are characteristic of Parkinson's disease. Chaperones, which ensure the correct folding of newly synthesised polypeptides, can inhibit α-synuclein aggregation and, as a consequence, prevent fibrils from forming. Researchers from Heidelberg have shown that a specific combination of human molecular chaperones is able to disassemble fibrils and transform them into non-toxic α-synuclein…

    https://www.gesundheitsindustrie-bw.de/en/article/news/chaperones-disassemble-parkinsons-disease-specific-amyloid-fibrils
  • Prenatal diagnosis - 23/03/2017 A transparent plastic disk and a microscope slide that is held with a pair of tweezers.

    Microdroplets for safe and rapid prenatal diagnoses

    Although the methods used to carry out amniocentesis are quite sophisticated, there is still a 0.5 percent risk of miscarriage following the intervention. Therefore, an EU-funded project called AngeLab is developing a rapid test that only requires a blood sample of the mother rather than amniotic fluid. The test yields information on the genetic health of the foetus within only a few hours. As part of the project, researchers from the…

    https://www.gesundheitsindustrie-bw.de/en/article/news/microdroplets-for-safe-and-rapid-prenatal-diagnoses
  • Article - 02/03/2017 Biosensor that looks very much like a computer chip.

    Personalised antibiotics therapy: fewer antibiotic-resistant bacteria

    Antibiotics have long been used as all-purpose weapons against infectious diseases – too often and too early, as we now know. This tendency has caused many bacteria to become resistant to standard antibiotics. The search for new substance classes has proved quite difficult. Care must therefore be taken to use existing antibiotics prudently in order to reduce the number of bacteria becoming resistant to them in the long term. Researchers from…

    https://www.gesundheitsindustrie-bw.de/en/article/news/personalised-antibiotics-therapy-fewer-antibiotic-resistant-bacteria
  • Article - 23/02/2017 Photo showing the two CEOs, Dr. Frank Mathias and Michael Scholl.

    Rentschler places formulation on biopharmaceuticals production agenda with LEUKOCARE alliance

    On February 2, 2017, Rentschler Biotechnologie and LEUKOCARE announced a strategic alliance in which LEUKOCARE will become the exclusive formulation developer for the Laupheim-based contract manufacturer. Rentschler will acquire a 10% stake in LEUKOCARE, a biotech company established in 2003 and headquartered in Martinsried. On behalf of BIOPRO, Walter Pytlik spoke with the two CEOs, Rentschler’s Dr. Frank Mathias and LEUKOCARE’s Michael Scholl…

    https://www.gesundheitsindustrie-bw.de/en/article/news/rentschler-places-formulation-on-biopharmaceuticals-production-agenda-with-leukocare-alliance
  • Press release - 07/02/2017

    Atriva receives seed financing to develop its next generation influenza therapeutic

    The next generation of Antiviral Therapies: Led by Stichting Participatie Atriva together with High-Tech Gründerfonds (HTGF), Atriva Therapeutics GmbH has received seed financing from Dutch and German private investors to advance Atriva’s antiviral MEK-Inhibitors (Mitogen-activated protein kinase kinase inhibitor) against Influenza into the clinical development stage.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/atriva-receives-seed-financing-to-develop-its-next-generation-influenza-therapeutic
  • Press release - 13/12/2016 A laboratory device being loaded with small reaction vessels.

    Early-diagnosis systems from Baden-Württemberg help prevent the spread of drug-resistant pathogens

    More and more bacteria are developing resistance to multiple antimicrobial drugs. These multidrug-resistant bacteria can impede the action of common antibiotics via mutations or DNA transfer. More than 30,000 people are infected every year with multidrug-resistant bacteria in German hospitals alone. This could be prevented with appropriate hygiene measures and innovative test systems. Innovative test systems that enable reliable and rapid…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/fruehdiagnostik-aus-baden-wuerttemberg-hilft-resistente-erreger-zu-stoppen
  • Press release - 12/12/2016

    Curetis obtains EIB debt financing totaling up to EUR 25 million to further expand its diagnostic platform

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/curetis-obtains-eib-debt-financing-totaling-up-to-eur-25-million-to-further-expand-its-diagnostic-platform
  • Expert interview - 14/11/2016 The photo shows a green plant.

    The great untapped potential of herbal medicines

    Baden-Württemberg is home to a large number of companies that produce herbal medicines, i.e. preparations made from plant extracts rather than pure compounds. In an interview with Dr. Ariane Pott from BIOPRO Baden-Württemberg, Professor Dr. Michael Wink, Director of the Institute of Pharmacy and Molecular Biotechnology at the University of Heidelberg, explains how these special extracts are placed on the market and how they differ from medicines…

    https://www.gesundheitsindustrie-bw.de/en/article/news/the-great-untapped-potential-of-herbal-medicines
  • Press release - 04/11/2016

    Atriva Therapeutics Announces Upcoming US Patent Issuance for MEK Treatment against Viral Diseases

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/atriva-therapeutics-announces-upcoming-us-patent-issuance-for-mek-treatment-against-viral-diseases
  • Article - 12/09/2016 Photo of the building housing the Department of Internal Medicine in Tübingen.

    New target for the therapy of hepatocellular carcinoma discovered

    Hepatocellular carcinoma is the second most common cause of cancer deaths worldwide. If the tumour is at an advanced stage, doctors have few treatment options. Researchers led by Prof. Dr. Lars Zender from the University of Tübingen have now identified one of the cancer's Achilles' heels, namely, the interaction between C-MYC and AURKA proteins, which can be destabilised with a drug, thus killing cancer cells.

    https://www.gesundheitsindustrie-bw.de/en/article/news/new-target-for-the-therapy-of-hepatocellular-carcinoma-discovered
  • Article - 18/08/2016 Schematic showing the excretion of toxic proteins. Specifically, the schematic shows a bacterial cell and a human cell (circles) and toxic products (small dots) that dock to cells.

    Moonlighting proteins can make bacteria pathogenic

    The mechanism underlying the export of biomolecules from cells remains unknown. Prof. Dr. Friedrich Götz and his team at the Institute of Microbial Genetics at the University of Tübingen have found out that staphylococci can turn into dangerous pathogens by excreting normally harmless enzymes. The researchers believe that the enigmatic excretion of such enzymes is due to a completely new mechanism and are thus planning to carry out further…

    https://www.gesundheitsindustrie-bw.de/en/article/news/moonlighting-proteins-can-make-bacteria-pathogenic
  • Article - 19/07/2016 Symbolic 3D model with a T cell equipped with CAR and the relevant DNA.

    Licence to kill – the enormous potential of CAR T cells

    With 6 million euros of EU funding, the CARAT project aims to optimise a technology called CAR T that is used to equip T cells with antibody fragments and specifically direct them to destroy cancer cells. The CARAT consortium comprises a multinational team of experts from the Institute for Cell- and Gene Therapy at the Freiburg University Medical Center led by Prof. Dr. Toni Cathomen and seven partner institutions. Cathomen’s team is developing…

    https://www.gesundheitsindustrie-bw.de/en/article/news/licence-to-kill-the-enormous-potential-of-car-t-cells
  • Article - 30/06/2016 Fettfaerbung_in_der_Leber_HZ_Mchn.jpg

    Why fasting is good for health

    A protein in the nucleus of liver cells is produced in greater quantities when we go hungry; it limits fatty acid uptake and adjusts the metabolism in the liver. However in people with metabolic disorders, the abnormal expression of this protein (GADD45β), which was previously only known to be involved in the regulation of cell division and DNA repair, leads to a dysregulated fat and sugar metabolism. Scientists from the DKFZ and Helmholtz…

    https://www.gesundheitsindustrie-bw.de/en/article/news/why-fasting-is-good-for-health
  • Company profile - 27/06/2016 Schematic showing a host cell that is infected by an influenza virus that uses the MEK signalling pathway in the host cells to propagate (left). Several new viruses (red) have been released by the host cell. The schematic on the right-hand side shows the blockage of the signalling pathway. Crossed-out grey virus cells below the host cell indicate that the viruses are no longer able to replicate.

    Atriva Therapeutics GmbH: new ways to treat influenza

    Influenza viruses constantly change and mutate. This makes treatment difficult and vaccination rather touch and go. But what about targeting virus-manipulated cell events rather than using the virus itself as drug target? Atriva Therapeutics GmbH, a start-up company from Tübingen, shows how this works.

    https://www.gesundheitsindustrie-bw.de/en/article/news/atriva-therapeutics-gmbh-new-ways-to-treat-influenza
  • Article - 20/06/2016 Photo showing a disk-shaped cartridge for use in a point-of-care system.

    New diagnostic tool for greater health safety when dealing with multidrug-resistant pathogens

    Infections with antibiotic-resistant bacteria and diseases such as breast or colon cancer are among the major causes of death worldwide. Early diagnosis is therefore key for the identification of people affected and for providing immediate therapy. The R&D service provider Hahn-Schickard and its partners are currently working on the development of a rapid and simple diagnostic system that can detect life-threatening infections and cancer at…

    https://www.gesundheitsindustrie-bw.de/en/article/news/new-diagnostic-tool-for-greater-health-safety-when-dealing-with-multidrug-resistant-pathogens
  • Researcher profile - 13/06/2016 3D matrix showing the relationships between Pseudomonas aeruginosa strains. Each strain is represented by a dot. The closer the strains are related to each other, the smaller the distance between them. The matrix shows four groups of strains in four different colours.

    Matthias Willmann wants to get the big picture – tracking down infectious agents

    While fighting and curing bacterial infections in sick patients is one part of the picture, epidemiological investigation of the spread of pathogens is another. Dr. Matthias Willmann also assesses the impact of these factors on the healthcare system as a whole and draws conclusions that might boost early detection of pathogens and prevention of infections.

    https://www.gesundheitsindustrie-bw.de/en/article/news/matthias-willmann-wants-to-get-the-big-picture-tracking-down-infectious-agents
  • Article - 26/04/2016 Photo showing a bottle with medicine that is dropped onto a spoon.

    Methadone for cancer treatment? Clinical trials are needed to prove the effectiveness of this opioid

    Claudia Friesen, an oncologist at Ulm University Hospital, has achieved what many scientists dream of: she has made a discovery that has increased existing knowledge, and can be used to help people. People with cancers that are resistant to all conventional therapies who have been given methadone for pain relief in combination with conventional chemo- or radiation therapy, have reported that tumours have shrunk or disappeared completely. Clinical…

    https://www.gesundheitsindustrie-bw.de/en/article/news/methadone-for-cancer-treatment-clinical-trials-are-needed-to-prove-the-effectiveness-of-this-opioid
  • Article - 25/04/2016 Trumpp_Andreas.jpg

    Pancreatic cancer and its resistance to therapy

    Pancreatic tumours are among the cancers with the worst prognosis. In many cases they are resistant to treatment. Prof. Dr. Andreas Trumpp and his colleagues from the DKFZ and the Heidelberg Institute for Stem Cell Technology and Experimental Medicine HI-STEM have discovered that the reason why some pancreatic tumours are so resistant to treatment is down to larger quantities of the enzyme CYP3A5 in subtypes of pancreatic cancer. Molecular…

    https://www.gesundheitsindustrie-bw.de/en/article/news/pancreatic-cancer-and-its-resistance-to-therapy
  • Article - 19/10/2015 Electron microscope image of MRSA bacteria: four green spheres surrounded by grey cellular material.

    New compound that may kill hospital germs is close to clinical testing

    Bacteria's increasing resistance to antibiotics is a very serious medical issue. An infection with pathogens such as methicillin-resistant Staphylococcus aureus (MRSA) bacteria can be life-threatening for hospital patients because MRSA has become resistant to the most commonly used antibiotics. Although reserve antibiotics are available in cases where others have lost their ability to control or kill bacterial growth effectively, they do not…

    https://www.gesundheitsindustrie-bw.de/en/article/news/new-compound-that-may-kill-hospital-germs-is-close-to-clinical-testing
  • Article - 17/08/2015 AG_Papatheodorou.jpg

    CDT – a bacterial toxin that mediates its own delivery into cells

    Clostridium difficile is totally harmless in healthy people. However, in combination with antibiotics it can cause severe diarrhoea and intestinal inflammation in elderly and debilitated people. But how does the spore-forming, rod-shaped bacterium deploy its power? And how does it enter the cell? Dr. Panagiotis Papatheodorou and his colleagues from the Institute of Experimental and Clinical Pharmacology and Toxicology (Director: Prof. Dr. Klaus…

    https://www.gesundheitsindustrie-bw.de/en/article/news/cdt-a-bacterial-toxin-that-mediates-its-own-delivery-into-cells
  • Article - 27/07/2015 Zender_Lars_Prof.jpg

    Looking for the Achilles’ heel of the tumour

    Although medicines that inhibit the growth of cancer cells are available, the prognosis for patients with solid tumours is generally still rather poor. The reason for this is that tumour cells develop resistance to therapy during treatment, and the tumour can continue to grow. However, tumours are vulnerable – if only more robust medicines were available. Prof. Dr. Lars Zender, senior physician and head of the Division of Translational…

    https://www.gesundheitsindustrie-bw.de/en/article/news/looking-for-the-achilles-heel-of-the-tumour
  • Article - 11/05/2015 B/w electron microscope image of a Lactobacillus rhamnosus bacterium that is in contact with a keratinocyte (measuring bar = 0.1).

    How Lactobacillus bacteria fight Candida albicans infections

    Fungal infections of skin and mucous membranes are relatively common. Around 75 percent of the human population lives with Candida albicans, a fungus that has no harmful effects in people with an intact immune system that can fight off systemic infections. However, in people with immune systems that have been weakened by antibiotics or radiotherapy for example C. albicans infections can lead to sepsis which may even be life-threatening. Prof. Dr.…

    https://www.gesundheitsindustrie-bw.de/en/article/news/how-lactobacillus-bacteria-fight-candida-albicans-infections

Page 2 / 9

sb_search.block.search_result.other.pages

  • eine Seite vor
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 9
  • eine Seite zurück
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • Telemedicine BW
    • MDR & IVDR
  • Portals
    • BIOPRO BW
    • Healthcare industry
    • Bioeconomy
  • To top

stay informed

Subscribe to newsletter

Social Media

  • Xing
  • Twitter
  • LinkedIn
  • Rss
  • Privacy statement
  • Legal notice
  • Sitemap
  • Contact
© 2021
Website address: https://www.gesundheitsindustrie-bw.de/en/search